NCT07614321RecruitingPhase 4
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
Is Silodosin Effective for Treating Lower Urinary Tract Symptoms in Female Patients With Multiple Sclerosis? A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS. Participants will: Take silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 7 May 2026
- Start date
- Apr 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Atlantic Health System
- Diseases
- Multiple sclerosis
- NCT number
- NCT07614321
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From Apr 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with alpha-blocker, B3 agonist, or anticholinergic medication within the last 6 weeks
- Treatment with sacral neuromodulation, bladder Botox, or posterior tibial nerve stimulation within the last 9 months
- Recent treatment with steroids in the last 3 months (this does not include one-time pre-treatment with steroids for administration of immunologic drug)
Other illness
- Renal impairment with CrCl \< 30
- Severe liver impairment (Child-Pugh class C)
Other
- PVR \> 300
- Diagnosed orthostatic hypotension
- Pregnancy or breastfeeding
- Current symptomatic kidney stones
- Recent MS relapse within the last 3 months
Who the study is looking for
- Female patients with a diagnosis of multiple sclerosis
- Age \> 18
- Moderate to severe lower urinary tract symptoms as defined by an AUASS score \> 8
- No UTI
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atlantic Health Coordinator of this site? Confirm its status | Morristown | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.